loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Masitinib Mesylate, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Masitinib Mesylate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Temad- We think of world-class quality.

    2D Structure
    1. Also known as: 1048007-93-7, Masitinib (mesylate), Masivet, Ab-1010 mesylate, Masitinib mesilate, Ab 1010 mesylate
    Molecular Formula
    C29H34N6O4S2
    Molecular Weight
    594.8  g/mol
    InChI Key
    TXCWBWKVIZGWEQ-UHFFFAOYSA-N
    FDA UNII
    ZK89EG3A18
    Masitinib Mesylate is the orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
    2.1.2 InChI
    InChI=1S/C28H30N6OS.CH4O3S/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34;1-5(2,3)4/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32);1H3,(H,2,3,4)
    2.1.3 InChI Key
    TXCWBWKVIZGWEQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    ZK89EG3A18
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide

    2. Ab 1010

    3. Ab-1010

    4. Ab1010

    5. Kinavet

    6. Kinavet Ca-1

    7. Masatinib

    8. Masican

    9. Masitinib

    10. Masitinib Mesilate

    11. Masitinib Methanesulfonate

    12. Masivet

    13. Masiviera

    2.3.2 Depositor-Supplied Synonyms

    1. 1048007-93-7

    2. Masitinib (mesylate)

    3. Masivet

    4. Ab-1010 Mesylate

    5. Masitinib Mesilate

    6. Ab 1010 Mesylate

    7. Kinavet

    8. Zk89eg3a18

    9. Masican

    10. Masiviera

    11. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulfonate

    12. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulphonate

    13. 4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide Methanesulfonate

    14. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulfonate (1:1)

    15. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulphonate (1:1)

    16. 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide Mesylate

    17. 928671-85-6

    18. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

    19. Unii-zk89eg3a18

    20. Masitinibmesylate

    21. Schembl1096348

    22. Dtxsid70146747

    23. Bcp30695

    24. Ex-a3996

    25. Masitinib Mesilate [who-dd]

    26. Yrb00793

    27. Hy-10209a

    28. Cs-1593

    29. Masitinib Mesylate [green Book]

    30. Masitinib Methanesulfonate [mi]

    31. Sb14845

    32. Ac-30896

    33. As-56731

    34. Ft-0707180

    35. C71194

    36. Masitinib Mesylate [ema Epar Veterinary]

    37. A927557

    38. Q27295645

    39. Ab1010 Mesylate;ab-1010 Mesylate;ab 1010 Mesylate

    40. Masitinib Mesylate Salt; Masitinib Mesilate;ab 1010 Mesylate Pound>>ab1010 Mesylate Pound>>ab-1010 Mesylate

    41. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate

    42. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate;

    2.4 Create Date
    2008-11-17
    3 Chemical and Physical Properties
    Molecular Weight 594.8 g/mol
    Molecular Formula C29H34N6O4S2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count7
    Exact Mass594.20829593 g/mol
    Monoisotopic Mass594.20829593 g/mol
    Topological Polar Surface Area164 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity788
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of amyotrophic lateral sclerosis.

    Treatment of mastocytosis

    Treatment of non resectable locally advanced or metastatic pancreatic cancer

    Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)

    Treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-KIT tyrosine-kinase receptor.

    Treatment of mastocytosis

    Treatment of gastro-intestinal stromal tumours

    Treatment of amyotrophic lateral sclerosis

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01XE22

    L01XE22

    L01XE

    L01XE

    QL01XE90

    Post Enquiry
    POST ENQUIRY